Quote:
Originally Posted by wkikta
The NMSS has invested $1 million in Apitope for their research. If it is successful they will share in the profits. The CRAB medications are more than $25,000 per year. oral laquinimod has been accepted by the FDA for fast track. It is looking better and better for the future.
|
Bill, since you dragged this thread up I will comment on it.
The clinical trial for Tovaxin was terminated due to lack of funding. According to the research I have done, they needed less than $400,000 to finish the Phase IIb open label trial in order to move forward to the Phase III trial. Myelin Repair Foundation pulled their funding/partnership which would have allowed this drug trial to continue.
No one has been able to get the attention of any other research/grant dollars to continue this so the 150 of us have been dropped. Period. We are left to find other methods to treat our MS. For a lot of us, this was a last resort. For some of us, since we were in this trial, it precludes us from eligibility for other clinical trials.
Since I am a volunteer as the Government Relations Chairman for the National MS Society for Idaho, you can bet that I will be speaking to this issue at the Public Policy Conference in DC in March.
This was the first drug that has worked for me and many others that were in this trial. A couple of us are writing letters to all the Legislators, the drug company, and anyone who will listen to us.